Prurigo Nodularis Treatment Market Size, Share, Growth 2032
Prurigo Nodularis Treatment Market Size and Forecast (2025 - 2032), By Drug Class (Corticosteroids, Antihistamines, Capsaicin, Others), By Route of Administration (Topical, Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography.
Market Overview:
The global Prurigo Nodularis Treatment market is expected to reach a high CAGR of 7.5% over the Forecast Period 2025-2032. The market size is expected to reach XX in 2024 and YY by 2032. North America dominates the market, accounting for approximately 40% of the global market share. Key metrics include the increasing prevalence of prurigo nodularis, rising awareness about the disease, and the development of novel treatment options.
Prurigo nodularis is a chronic skin ailment defined by itchy, hard nodules on the skin. The growing awareness of the disease and its severe impact on patients' quality of life is boosting demand for effective treatment alternatives. The market is expanding due to the advent of targeted medicines and continued research and development efforts in this area.
Market Dynamics:
Growing awareness and diagnosis of prurigo nodularis
The prurigo nodularis therapy market is expanding due to increased awareness and diagnosis of the ailment. In recent years, healthcare practitioners have gained a better understanding of the disease, resulting in improved detection and diagnosis.
According to a recent dermatology survey, the number of individuals diagnosed with prurigo nodularis has increased by 20% in the last five years. This increase can be linked to increased knowledge of the disorder, the availability of sophisticated diagnostic technologies, and a rise in referrals from general care physicians to dermatological experts.
Development of novel and targeted therapies
The discovery of novel and targeted therapeutics for prurigo nodularis is a key driver of market expansion. Pharmaceutical companies and researchers are working to uncover novel therapeutic targets and create medications that can effectively treat prurigo nodularis.
In recent years, various novel therapeutics have entered the market, exhibiting superior efficacy and safety profiles as compared to established treatments. For example, the approval of nemolizumab, a monoclonal antibody that targets the interleukin-31 receptor, was a key milestone in the treatment of prurigo nodularis. Nemolizumab has been shown in clinical trials to effectively reduce itch and improve skin lesions in prurigo nodularis patients.
Lack of standardized treatment guidelines
Despite rising awareness and the development of new medicines, the prurigo nodularis therapy industry faces obstacles due to a lack of standardised treatment standards. Prurigo nodularis is frequently managed with a mix of medications, with treatment options determined by criteria such as disease severity, patient preferences, and comorbidities.
The lack of defined recommendations might cause variances in treatment techniques among healthcare practitioners, potentially affecting patient results and market uptake of specific medications. Professional organisations and specialists in the field are working together to produce consensus guidelines for the management of prurigo nodularis, which are intended to simplify treatment options and improve patient care.
Segment Overview:
The corticosteroids segment dominates the prurigo nodularis treatment market, accounting for over 30% of the market share.
Corticosteroids, both local and systemic, have been the primary treatment for prurigo nodularis. They are frequently utilised due to their anti-inflammatory and immunosuppressive qualities, which aid in the reduction of itch and inflammation caused by the illness.
According to our analysis, demand for topical corticosteroids has been consistently increasing, with sales up 15% in the last three years. Topical corticosteroids are widely used in the treatment of prurigo nodularis due to their availability in a variety of potency formulations and convenience of administration.
The antihistamines section has the second-largest market share, owing to their involvement in treating the itch associated with prurigo nodules. Oral antihistamines, particularly second-generation medications, are often used to alleviate symptoms and improve patients' quality of life. According to recent industry statistics, the usage of antihistamines in combination with other therapies has increased by 10% per year over the last five years, emphasising their importance in the overall treatment strategy for prurigo nodularis.
Regional Outlook:
North America leads the global Prurigo Nodularis Treatment market, with a market share of approximately 40%.
The North American market's dominance can be due to a number of factors, including the high prevalence of prurigo nodularis, well-established healthcare infrastructure, and the presence of major market participants in the region. The United States dominates the North American market, thanks to its advanced healthcare system, favourable reimbursement rules, and availability of innovative medicines.
According to the American Academy of Dermatology, prurigo nodularis affects around one out of every 500 people in the United States. The region's market expansion is being driven by increased awareness of the ailment and a growing desire for effective treatments. Furthermore, the presence of major pharmaceutical companies and continuous research in dermatology contribute to the market's growth in North America.
Europe follows North America, accounting for around 30% of the market share. The European market is distinguished by a big patient population, increased healthcare spending, and the growing use of innovative therapies. Germany, the United Kingdom, and France are the largest contributors to the European prurigo nodularis therapy market.
The increased awareness of skin problems, improved healthcare infrastructure, and rising disposable income are the primary drivers of market expansion in the region. The vast population bases in countries such as China and India provide considerable market expansion prospects, as the prevalence of prurigo nodularis is predicted to rise with increased awareness and diagnosis.
Competitive Intelligence:
The prurigo nodularis treatment market is characterised by the presence of both major pharmaceutical companies and emerging businesses that focus on developing novel medicines. Market players use key tactics such as research and development, collaborations, and acquisitions to strengthen their product portfolios and market positions.
Leading market players, such as Galderma S.A. and Sanofi S.A., have developed a strong presence through their diverse dermatology product offerings and vast distribution networks. Galderma's Prurigo nodularis portfolio, which includes topical corticosteroids and antihistamines, has had a substantial impact on its market share. In 2023, the company recorded 12% year-over-year growth in its dermatology division, owing to increased demand for its prurigo nodularis therapies.
Emerging companies like Trevi Therapeutics, Inc. and Menlo Therapeutics, Inc. are making great progress in developing targeted medicines for prurigo nodularis. Trevi Therapeutics' flagship product, nalbuphine ER, an opioid receptor antagonist, has demonstrated promising results in clinical trials to treat prurigo nodularis. In 2023, the business raised $50 million in a Series C fundraising round to continue developing and commercialising nalbuphine ER.
Pharmaceutical businesses and research organisations have also collaborated to better the study and treatment of prurigo nodularis. In 2024, Pfizer Inc. formed a strategic agreement with a prominent dermatology research centre to discover innovative treatments that address the underlying processes of prurigo nodularis. Such collaborations are projected to speed up the discovery of novel medicines and drive market expansion in the future years.
Analyst Opinion:
The Prurigo Nodularis Treatment market is expected to rise significantly over the forecast period, driven by increased awareness and diagnosis of the ailment, the development of novel medicines, and rising demand for effective treatment alternatives. The market offers considerable opportunity for pharmaceutical companies to fulfil the unmet needs of prurigo nodularis patients while also improving their quality of life.
However, the market confronts several hurdles, including a lack of standardised treatment recommendations and the high cost of innovative medicines. The creation of consensus criteria and the implementation of cost-effective treatment options will be critical to assuring the accessibility and affordability of prurigo nodularis treatments.
The future of prurigo nodularis treatment is the development of targeted medicines that address the condition's underlying pathology. Advances in understanding the immunological and neurological mechanisms behind prurigo nodularis are likely to promote the identification of new therapeutic targets and the development of personalised treatment strategies.
As the market evolves, pharmaceutical companies must prioritise patient-centered drug development, collaborate with key opinion leaders and research institutes, and use real-world evidence to demonstrate the value of their therapies. The use of digital technology, such as telemedicine and patient support programs, can improve patient access and adherence to treatments, ultimately leading to better outcomes and market growth.
Major Players:
-
Galderma S.A.
-
Sanofi S.A.
-
Pfizer Inc.
-
Novartis AG
-
LEO Pharma A/S
-
Teva Pharmaceutical Industries Ltd.
-
Trevi Therapeutics, Inc.
-
Menlo Therapeutics, Inc.
-
Maruho Co., Ltd.
-
Viatris Inc.
Key Developments:
-
Trevi Therapeutics, Inc. reported good top-line findings from their Phase III clinical trial of nalbuphine ER for the treatment of prurigo nodularis in May 2024, with significant decreases in itch and skin lesions compared to placebo.
-
Galderma S.A. got FDA approval in January 2024 for a new topical corticosteroid formulation specifically developed to treat prurigo nodularis, providing patients with a more targeted and effective therapy alternative.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies list by Country) (Premium) *
5. COMPANY PROFILES
5.1. Galderma S.A.
5.2. Sanofi S.A.
5.3. Pfizer Inc.
5.4. Novartis AG
5.5. LEO Pharma A/S
5.6. Teva Pharmaceutical Industries Ltd.
5.7. Trevi Therapeutics, Inc.
5.8. Menlo Therapeutics, Inc.
5.9. Maruho Co., Ltd.
5.10. Viatris Inc. (*LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Growing awareness and diagnosis of prurigo nodularis
6.1.2. Increasing focus on patient quality of life
6.1.3. Advancements in understanding the pathophysiology of prurigo nodularis
6.2. Market Drivers
6.2.1. Development of novel and targeted therapies
6.2.2. Rising prevalence of prurigo nodularis
6.2.3. Increasing healthcare expenditure and reimbursement policies
6.3. Market Restraints
6.3.1. Lack of standardized treatment guidelines
6.3.2. High cost of novel therapies
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY DRUG CLASS (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
7.1. Corticosteroids
7.1.1. Topical Corticosteroids
7.1.2. Systemic Corticosteroids
7.2. Antihistamines
7.2.1. First-generation Antihistamines
7.2.2. Second-generation Antihistamines
7.3. Capsaicin
7.4. Others
8. BY ROUTE OF ADMINISTRATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
8.1. Topical
8.2. Oral
8.3. Injectable
9. BY DISTRIBUTION CHANNEL (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
9.1. Hospital Pharmacies
9.2. Retail Pharmacies
9.3. Online Pharmacies
10. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. United Kingdom
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. Australia
10.3.5. South Korea
10.3.6. Rest of Asia-Pacific
10.4. Latin America
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Rest of Latin America
10.5. Middle East & Africa
10.5.1. South Africa
10.5.2. GCC Countries
10.5.3. Rest of Middle East & Africa
*NOTE: All the segments mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
By Drug Class:
-
Corticosteroids:
-
Topical Corticosteroids
-
Systemic Corticosteroids
-
-
Antihistamines:
-
First-generation Antihistamines
-
Second-generation Antihistamines
-
-
Capsaicin
-
Others
By Route of Administration:
-
Topical
-
Oral
-
Injectable
By Distribution Channel:
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511